University of Virginia
Subjects with urgently reperfused type I myocardial infarction (MI) will be recruited and randomized to receive either placebo or the oral inflammasome (NLRP3) inhibitor dapansutrile. The primarily outcome measure will be carotid plaque volume change over 6 months; secondary outcome measures will be plaque inflammatory activity and coronary microvascular function.
Inclusion Criteria: * Acute type I myocardial infarction (NSTEMI or STEMI) * Reperfusion therapy planned or performed within prior 48 hrs * Carotid or femoral artery plaque at baseline, or carotid intima media thickness \>1.5 mm Exclusion Criteria: * Type II MI * Failed primary PCI or need for emergent bypass surgery * Severe heart failure (NYHA class IV) * Life-threatening complication of MI (myocardial rupture, ischemic VSD, papillary muscle rupture) * Refractory ventricular arrhythmias * Allergy to dapansutril, OLT177, or drugs in the same class * Co-morbidity limiting 6 month survival *…
Oral inhibitor of NLRP3
Non-active placebo
Arctuva estimate
Verify or correct the compensation shown for this listing.